Claims Scope:

Patent issued March 19, 2019. 

 

Sequence-specific Composition & Method claims 

– lentiviral vector (claim 1)  

– treating cells infected with HIV (claim 9) 

– lentiviral particle (claim 3) 

-modified CD4 Cell (claim 6) 

– sequence specific limitations include: 

1. SEQ ID NO: 31 (CCR5, Vif and Tat microRNA cluster) (claim 1; 9; 3; 6), 

(with sequence identity limitation (e.g., at least 80% or 85% )).